Brannagan, T. H., Coelho, T., Wang, A. K., Polydefkis, M. J., Dyck, P. J., Berk, J. L., . . . Gertz, M. (2022). Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
Chicago Style (17th ed.) CitationBrannagan, Thomas H., et al. Long-term Efficacy and Safety of Inotersen for Hereditary Transthyretin Amyloidosis: NEURO-TTR Open-label Extension 3-year Update. 2022.
MLA (8th ed.) CitationBrannagan, Thomas H., et al. Long-term Efficacy and Safety of Inotersen for Hereditary Transthyretin Amyloidosis: NEURO-TTR Open-label Extension 3-year Update. 2022.
Warning: These citations may not always be 100% accurate.